Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

NCT07197450 | Recruiting Early Phase 1

• 1 other identifier: K6744
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the safety and efficacy of a novel PTH replacement therapy drug in patients with hypoparathyroidism. The drug is an mRNA drug which will be translated into PTH after intravenous administration, to achieve the therapeutic effect.

Conditions

Hypoparathyroidism

Keywords

hypoparathyroidism; PTH; mRNA

Outcome Measures

Primary Outcomes (1)

• AE and SAE

  adverse event (AE) and severe adverse event (SAE) via regular vital sign checks， physical examinations, and safety laboratory tests (including complete blood count, blood biochemistry, coagulation profile, C-reactive protein, urinalysis, cardiac ultrasound, and electrocardiogram).

  the whole study period including the screening, treatment, and follow-up period. Follow-up period extends to 90 days after administration.

Secondary Outcomes (10)

• PTH1-84

  Before (within 1 hour) and 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration

• PTH

  Before (within 1 hour) and 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration

• serum calcium

  Before (within 1 hour) and 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration

• Serum magnesium

  Before (within 1 hour) and 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration

• Serum phosphorus

  Before (within 1 hour) and 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration

Study Arms (5)

20ug

EXPERIMENTAL

PTH1-84 mRNA 20ug

Drug: intravenous administration of PTH1-84 mRNA

40ug

EXPERIMENTAL

PTH1-84 mRNA 40ug

Drug: intravenous administration of PTH1-84 mRNA

80ug

EXPERIMENTAL

PTH1-84 mRNA 80ug

Drug: intravenous administration of PTH1-84 mRNA

120ug

EXPERIMENTAL

PTH1-84 mRNA 120ug

Drug: intravenous administration of PTH1-84 mRNA

160ug

EXPERIMENTAL

PTH1-84 mRNA 160ug

Drug: intravenous administration of PTH1-84 mRNA

Interventions

intravenous administration of PTH1-84 mRNA DRUG

intravenous administration of PTH1-84 mRNA

120ug; 160ug; 20ug; 40ug; 80ug

Eligibility Criteria

• Age: 18 Years - 65 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 to 65 years (inclusive), male or female.
• Documented history of post-surgical chronic HP or autoimmune, genetic, or idiopathic HP for at least 26 weeks. Diagnosis of HP is confirmed based on a history of hypocalcemia accompanied by an inappropriately low serum PTH level (below the upper limit of the normal range of the local laboratory). \* Note: If a subject lacks documented diagnosis of chronic HP but has exhibited hypocalcemia accompanied by an inappropriately low serum PTH level for at least 26 weeks prior to screening, and is judged by the investigator to meet the diagnostic criteria for chronic HP, they will be considered eligible for this criterion.
• Poorly controlled or intolerant to conventional therapy (calcium and active vitamin D).
• Conventional therapy (including vitamin D or magnesium supplements, if applicable) can be optimized during the screening period to achieve the following target serum levels: 25(OH) Vitamin D level: 10 - 100 ng/mL (25 - 250 nmol/L, inclusive). Blood magnesium level: Within the normal range or slightly below, i.e., ≥ 1.3 mg/dL (≥ 0.53 mmol/L). Albumin-corrected serum calcium (sCa) level: Within the normal range or slightly below
• Body Mass Index (BMI) of 17 to 40 kg/m² (inclusive) at screening.
• If aged ≤ 25 years, radiological evidence of closed epiphyses based on X-ray of the non-dominant hand (wrist and palm).

You may not qualify if:

• Impaired PTH response (pseudohypoparathyroidism), characterized by PTH resistance and elevated PTH levels in the presence of hypocalcemia.
• History of allergic predisposition, or known allergy to the investigational drug or polyethylene glycol (PEG)-containing medications.
• Any disease other than HP that may affect calcium metabolism, calcium-phosphate homeostasis, or PTH levels, such as: active hyperthyroidism; Paget's disease of bone; severe hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes (HbA1c \>9%; HbA1c results from within 12 weeks prior to screening are acceptable); severe and chronic liver or kidney disease; Cushing's syndrome; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobilization; active malignancy (except for low-risk, well-differentiated thyroid cancer or non-melanoma skin cancer); active hyperparathyroidism; history of parathyroid carcinoma within 5 years prior to screening; acromegaly; or multiple endocrine neoplasia syndromes.
• History of vaccination within 4 weeks prior to enrollment, or planned vaccination during the study period.
• Pregnant or lactating women.
• Patients with high-risk thyroid cancer requiring TSH suppression \<0.2 mIU/L within the past 2 years, or patients with a history of malignancy.
• Requirement for long-term use of the following medications: diuretics, phosphate binders (except calcium supplements), digoxin, lithium, methotrexate, biotin \>30 μg/day, or systemic corticosteroids (except as replacement therapy). Patients requiring long-term use of hormones or immunosuppressants (e.g., for rheumatologic/autoimmune diseases) are excluded. \*Note: Subjects who can discontinue these medications for the study may be enrolled, provided the medications are stopped for at least 5.5 half-lives prior to blood sampling at Visit 1. Biotin must be stopped for at least 1 day prior to blood sampling during the screening period. These medications are prohibited throughout the entire study.\*
• Use of PTH-like drugs (whether commercially available or obtained through participation in a clinical trial), including PTH(1-84), PTH(1-34), other N-terminal fragments or analogs of PTH, or PTH-related protein, within 4 weeks prior to screening.
• Participation in any other interventional trial involving an investigational drug or device within 8 weeks prior to screening, or within 5.5 half-lives of the administered drug from the previous trial (whichever is longer).
• Uncontrolled hypertension at baseline, OR a history of the following cardiovascular and cerebrovascular diseases: (1) Unstable angina; (2) Drug-requiring or severe arrhythmia; (3) Myocardial infarction; (4) Class III or higher heart failure (NYHA classification), or second-degree or higher atrioventricular block; (5) Cerebral infarction (except lacunar infarction), cerebral hemorrhage, or related diseases.
• Increased risk of osteosarcoma, such as Paget's disease of bone or unexplained elevated alkaline phosphatase; hereditary disorders predisposing to osteosarcoma; or patients who have received extensive external beam radiation therapy or implant radiation involving the skeleton.
• Clinically significant abnormal laboratory findings at screening, including any of the following:
• Hematology: Neutrophil count (NEUT#) \<1.5 × 10⁹/L; Platelet count (PLT) \<90 × 10⁹/L; Hemoglobin (Hb) \<90 g/L; Eosinophil count (EOS#) \>0.5 × 10⁹/L.
• Liver and Renal Function: Total bilirubin, Alanine Aminotransferase (ALT), or Aspartate Aminotransferase (AST) above the normal range; estimated Glomerular Filtration Rate (eGFR) \<60 mL/min/1.73m².
• Any medical or other condition that, in the judgment of the Investigator, may affect the conduct of the study, interfere with the interpretation of study results, or pose an increased risk to the subject or the study.

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

Study Sites (1)

Peking Union Medical College Hospital

Beijing, 100730, China

RECRUITING

MeSH Terms

Conditions

Hypoparathyroidism

Condition Hierarchy (Ancestors)

Parathyroid Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: accelerated titration combined with a 3+3 design

Study Record Dates

• First Submitted: September 14, 2025
• First Posted: September 29, 2025
• Study Start: May 20, 2025
• Primary Completion: April 15, 2026
• Study Completion: April 30, 2026
• Last Updated: March 27, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)